CD274 and melanoma: PD-1 inhibitors (nivolumab, pembrolizumab) have been approved in therapy-refractory malignant melanoma, and together with PD-L1 inhibitors (MPDL3280A, MEDI4736) are investigated in clinical trials on various recurrent or metastatic malignancies to date.